DUBLIN–(BUSINESS WIRE)–The “Prenatal Diagnostics: Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
Global Prenatal Diagnostics Market to Reach $9.3 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Prenatal Diagnostics, estimated at US$4 Billion in the year 2020, is projected to reach a revised size of US$9.3 Billion by 2027, growing at a CAGR of 12.9% over the analysis period 2020-2027. Non-Invasive, one of the segments analyzed in the report, is projected to record 16% CAGR and reach US$6.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Invasive segment is readjusted to a revised 7.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 17.2% CAGR
The Prenatal Diagnostics market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 17.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 11.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR.
Select Competitors (Total 43 Featured) –
ANGLE Plc
Berry Genomics Co. Ltd.
BGI Genomics
F. Hoffmann-La Roche Ltd.
Hologic Inc.
Illumina Inc.
Laboratory Corporation of America Holdings
Lifecodexx AG
Natera Inc.
Quest Diagnostics Inc.
Ravgen Inc.
Sequenom Inc.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Non-Invasive Prenatal Testing (NIPT) Transforms Prenatal Testing Landscape
Major Factors Influencing Penetration of NIPT
NIPT Eliminates Risks & Uncertainty of Conventional Procedures
Replacing Screening Tests – A More Conceivable Change through NIPT
Diversity in NIPT Usage on the Cards
Benefits Outweigh Snags in NIPT Tests
Whole Genome Sequencing Technology in NIPT
DNA – More Ideal Target for NIPT Analysis than Whole Cells
Conventional Invasive Techniques Loose Sheen
Chromosomal Abnormalities Lead the Prenatal Testing Space
Chromosomal Abnormalities – A Substantial Economic Burden
List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
Significant Opportunities in Down’s Syndrome Testing
List of Select Screening Tests Available for T21 Screening and Confirmation
Beyond Down’s Syndrome – Need to Test Additional Targets Crucial
ACOG and ACGM Recommendations Boost Demand for Prenatal CF Testing
Prenatal Testing Crucial to Detect Risk of Huntington’s Disease
Increasing Congenital Disorder Incidence – Key Driver for Prenatal Diagnostics
Prenatal Testing – Effective Way of Alleviating Syphilis Related Deaths and Stillbirths
Molecular Diagnostics Widen Scope & Span of Prenatal Testing
NGS & MPS – Enabling Shorter Time to Test Results
Microarray-Based Prenatal Testing Gathers Steam
Sequencing in Prenatal Testing – A Potential High Growth Market
Ultrasound – An Indispensable Combination with Blood Based Screening Tests
New Sub-Targets on the Anvil for Ultrasound-Based Screening
Counseling – An Imperative Measure Before and After Prenatal Testing
Role of Prenatal Testing in Managing Preterm Births
Lower Sensitivity & Specificity of Existing Tests – A Case for New Tests on the Anvil
High Sensitivity Serum Tests May Not Have Many Takers
Ballooning Global Female Population Offers Increased Growth Opportunities
Issues & Challenges
Prenatal Diagnostics: Treading Sensitive Ethical Issues
Controversy Related to “Incidental Findings” of Prenatal Tests
Opposition to NIPT Technique – A Significant Hurdle to Adoption
Unresolved Issues Hamper Widespread Testing for Monogenetic Disease
Dearth of Genetic Counselors – A Major Hurdle for Genetic Testing
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
Companies Mentioned
ANGLE Plc
Berry Genomics Co. Ltd.
BGI Genomics
F. Hoffmann-La Roche Ltd.
Hologic Inc.
Illumina Inc.
Laboratory Corporation of America Holdings
Lifecodexx AG
Natera Inc.
Quest Diagnostics Inc.
Ravgen Inc.
Sequenom Inc.
For more information about this report visit https://www.researchandmarkets.com/r/c0qvsr
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
